Subjective feeling of control during fNIRS-based neurofeedback targeting the DL-PFC is related to neural activation determined with short-channel correction.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
12
2022
accepted:
31
07
2023
medline:
18
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Neurofeedback (NF) training is a promising preventive and therapeutic approach for brain and behavioral impairments, the dorsolateral prefrontal cortex (DL-PFC) being a relevant region of interest. Functional near-infrared spectroscopy (NIRS) has recently been applied in NF training. However, this approach is highly sensitive to extra-cerebral vascularization, which could bias measurements of cortical activity. Here, we examined the feasibility of a NF training targeting the DL-PFC and its specificity by assessing the impact of physiological confounds on NF success via short-channel offline correction under different signal filtering conditions. We also explored whether the individual mental strategies affect the NF success. Thirty volunteers participated in a single 15-trial NF session in which they had to increase the oxy-hemoglobin (HbO2) level of their bilateral DL-PFC. We found that 0.01-0.09 Hz band-pass filtering was more suited than the 0.01-0.2 Hz band-pass filter to highlight brain activation restricted to the NF channels in the DL-PFC. Retaining the 10 out of 15 best trials, we found that 18 participants (60%) managed to control their DL-PFC. This number dropped to 13 (43%) with short-channel correction. Half of the participants reported a positive subjective feeling of control, and the "cheering" strategy appeared to be more effective in men (p<0.05). Our results showed successful DL-PFC fNIRS-NF in a single session and highlighted the value of accounting for extra cortical signals, which can profoundly affect the success and specificity of NF training.
Identifiants
pubmed: 37585456
doi: 10.1371/journal.pone.0290005
pii: PONE-D-22-34461
pmc: PMC10431651
doi:
Substances chimiques
Oxyhemoglobins
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290005Informations de copyright
Copyright: © 2023 Godet et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuropsychologia. 2021 Jul 16;157:107866
pubmed: 33932482
J Neural Transm (Vienna). 2019 Sep;126(9):1175-1185
pubmed: 30498952
Neurophotonics. 2020 Jul;7(3):035009
pubmed: 32995361
Front Hum Neurosci. 2013 Oct 18;7:695
pubmed: 24151462
IEEE J Biomed Health Inform. 2018 Jul;22(4):1148-1156
pubmed: 28692996
Phys Med Biol. 1988 Dec;33(12):1433-42
pubmed: 3237772
Front Hum Neurosci. 2019 Jan 11;12:505
pubmed: 30687038
Neuroimage. 2016 Jan 1;124(Pt A):806-812
pubmed: 26419389
J Biophotonics. 2019 Sep;12(9):e201800298
pubmed: 30963713
Biomed Opt Express. 2013 Jul 17;4(8):1366-79
pubmed: 24009999
Front Syst Neurosci. 2022 Feb 10;16:774475
pubmed: 35221936
Neurophotonics. 2014 Jul;1(1):015002
pubmed: 26157972
Neurophotonics. 2021 Jan;8(1):012101
pubmed: 33442557
Nat Rev Neurosci. 2017 Feb;18(2):86-100
pubmed: 28003656
Behav Res Methods. 2019 Feb;51(1):195-203
pubmed: 30734206
Neuroimage Clin. 2015 Mar 24;8:1-31
pubmed: 26110109
Sci Rep. 2021 Aug 19;11(1):16873
pubmed: 34413344
Front Hum Neurosci. 2021 Mar 17;15:620342
pubmed: 33815078
Stroke. 2013 Apr;44(4):1091-8
pubmed: 23404723
Brain. 2020 Jun 1;143(6):1674-1685
pubmed: 32176800
Front Hum Neurosci. 2015 Jan 07;8:1038
pubmed: 25610390
Front Neurosci. 2020 Jul 21;14:594
pubmed: 32848528
Ann N Y Acad Sci. 2020 Mar;1464(1):5-29
pubmed: 30085354
Front Hum Neurosci. 2020 Jun 10;14:218
pubmed: 32587509
Front Hum Neurosci. 2016 Dec 16;10:633
pubmed: 28018199
Neurophotonics. 2019 Apr;6(2):025011
pubmed: 31930153
Neuroimage. 2016 Jul 1;134:153-159
pubmed: 27015711
Neuroimage. 2014 Jan 15;85 Pt 1:478-88
pubmed: 23578578
Neuroimage. 2014 Jan 15;85 Pt 1:6-27
pubmed: 23684868
Neuropsychopharmacology. 2022 Mar;47(4):944-952
pubmed: 34999737
Neuroimage. 2012 May 15;61(1):70-81
pubmed: 22426347
Front Comput Neurosci. 2016 Jul 12;10:70
pubmed: 27462216
Int J Environ Res Public Health. 2022 May 02;19(9):
pubmed: 35564926
Front Hum Neurosci. 2017 Sep 04;11:425
pubmed: 28928644
Neurophotonics. 2017 Oct;4(4):045003
pubmed: 29152530
Neurosci Biobehav Rev. 2016 Sep;68:891-910
pubmed: 27339691
PLoS One. 2013 Aug 01;8(8):e66319
pubmed: 23936292
Neurophotonics. 2015 Apr;2(2):025005
pubmed: 26158009
Neurosci Biobehav Rev. 2020 Nov;118:681-688
pubmed: 32918947
Front Hum Neurosci. 2014 Nov 06;8:894
pubmed: 25414659
PLoS One. 2020 Dec 23;15(12):e0244186
pubmed: 33362260
Trials. 2017 Jan 24;18(1):41
pubmed: 28118856
Neuroimage. 2019 Feb 1;186:256-265
pubmed: 30423429
Front Hum Neurosci. 2014 May 27;8:348
pubmed: 24904384
Psychiatry Clin Neurosci. 2016 Nov;70(11):507-516
pubmed: 27489230
Neuroimage. 2018 May 15;172:786-807
pubmed: 29288868
Neuroimage. 2012 Feb 1;59(3):2518-28
pubmed: 21945793
Neuroimage Clin. 2021;30:102577
pubmed: 33545580